retatrutide phase 2 nejm 2023 weight loss percent 48 weeks 2023年度回顧】 Notable Articles of Day 3: Triple–Hormone-Receptor Agonist for Obesity — A Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Retatrutide for Obesity: Phase 2
Description
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes
Planning this transition with a healthcare provider helps manage these risks and reduce unwanted effects
However, macronutrient profiles of what people ate remained the same before and after initiation of the drug
Yaffe et al., 2024)
Average weight loss by dose: Retatrutide 12mg: 28.7% body weight reduction (approx
Interestingly, insulin decreased markedly from 15.610.4 to 9.34.2 (p = 0.000) in the EGCG group and from 17.014.8 to 12.37.5 (p = 0.039) in the placebo group
